ProteoTech
Advancing Therapeutics and Diagnostics for Amyloid Diseases Since 1996
Advancing Therapeutics and Diagnostics for Amyloid Diseases Since 1996
ProteoTech is a US-based pharmaceutical company founded in 1996, dedicated to advancing therapeutics and diagnostics for amyloid diseases. The company's product lineup includes Exebryl-1, which targets the prevention of beta-amyloid protein formation, PeptiClere for Alzheimer's treatment, Synuclere for Parkinson's disease, and Systebryl for systemic amyloidosis associated with type 2 diabetes. At a last investment round in June 2011, ProteoTech secured $10.02M in venture capital. Based in Kirkland, Washington, ProteoTech aims to provide solutions for amyloid diseases, including Alzheimer's and Parkinson's.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $10.02M | - | 28 Jun 2011 | |
| Debt Financing | $519.40K | - | 28 Apr 2009 |
No recent news or press coverage available for ProteoTech.
We care about your data, and we'd love to use cookies make your experience better.
